GSA Capital Partners LLP Sells 336,014 Shares of Savara Inc. $SVRA

GSA Capital Partners LLP reduced its stake in Savara Inc. (NASDAQ:SVRA) by 47.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 372,449 shares of the company’s stock after selling 336,014 shares during the period. GSA Capital Partners LLP’s holdings in Savara were worth $1,330,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Prudential Financial Inc. bought a new position in Savara in the 2nd quarter worth about $30,000. BNP Paribas Financial Markets grew its holdings in shares of Savara by 52.3% during the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock valued at $31,000 after buying an additional 4,626 shares during the last quarter. May Hill Capital LLC bought a new stake in shares of Savara during the second quarter valued at approximately $32,000. Brevan Howard Capital Management LP purchased a new position in Savara in the 2nd quarter worth approximately $33,000. Finally, Quadrature Capital Ltd purchased a new position in Savara in the 2nd quarter worth approximately $42,000. 87.93% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have commented on SVRA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Savara in a research note on Thursday, January 22nd. HC Wainwright boosted their target price on Savara from $8.00 to $10.00 and gave the stock a “buy” rating in a research report on Tuesday, December 23rd. Guggenheim restated a “buy” rating on shares of Savara in a research note on Tuesday, December 23rd. Citizens Jmp dropped their price target on shares of Savara from $11.00 to $10.00 and set a “market outperform” rating on the stock in a report on Thursday, November 13th. Finally, Citigroup reissued an “outperform” rating on shares of Savara in a report on Thursday, October 23rd. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $8.86.

Savara Stock Performance

NASDAQ:SVRA opened at $5.59 on Thursday. The stock has a 50-day simple moving average of $5.91 and a two-hundred day simple moving average of $4.63. Savara Inc. has a 52-week low of $1.89 and a 52-week high of $7.01. The company has a debt-to-equity ratio of 0.32, a quick ratio of 7.65 and a current ratio of 7.65. The firm has a market capitalization of $1.14 billion, a PE ratio of -10.55 and a beta of 0.34.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.